RecruitingNCT07416461

Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease

Studying Invasive non-typhoidal salmonellosis

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: International Vaccine Institute
Principal Investigator: Octavie Lunguya
Institut National de Recherche Biomedicale
Intervention: R21/Matrix-M malaria vaccine(biological)
Enrollment: 10000 enrolled
Eligibility: All sexes
Timeline: 2025 – 2027

Study locations (1)

Institut National de Recherche Biomedicale (INRB), Kinshasa, Democratic Republic of the Congo

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07416461 on ClinicalTrials.gov

Other trials for Invasive non-typhoidal salmonellosis

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNANCT05870150
Challenge Non-Typhoidal Salmonella (CHANTS) Study
Imperial College Healthcare NHS Trust

See all trials for Invasive non-typhoidal salmonellosis →

← Back to all trials